Concepedia

Gerald Shockey

GS

Statistics

Publications

5

Citations

389

H-Index

5

Active since

2005

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Gerald Shockey is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, vaccine development, and vaccine safety.

Top concepts

Publications per year

2005–2024

5

Publications

5

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Sam Jackson, Joseph R. Lentino, James Kopp et al. · Vaccine · 2017 · 185 citations · Full text

Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

John B. Buse, Cindy J. Rubin, Robert Frederich et al. · Clinical Therapeutics · 2005 · 98 citations

, , +7

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes

Kun‐Ho Yoon, Gerald Shockey, R. Teng et al. · International Journal of Clinical Practice · 2011 · 51 citations

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx et al. · The Lancet Infectious Diseases · 2024 · 41 citations

, , +6

Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study

Ira Klimberg, Gerald Shockey, Howard Ellison et al. · Current Medical Research and Opinion · 2005 · 14 citations

1–5 of 5